Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NCT05607420)
Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)
🩺 Plain-English Summary (8th-Grade Level)
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Who can join: Review the eligibility criteria below.
Location: The University of Chicago Medical Center (UCMC) — Chicago, Illinois
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- The University of Chicago Medical Center (UCMC) — Chicago, Illinois
- Harvard Medical School - Massachusetts General Hospital — Boston, Massachusetts
- Rutgers Cancer Institute of New Jersey (CINJ) - New Brunswick — New Brunswick, New Jersey
- Sarah Cannon - St. David South Austin Medical Center — Austin, Texas
- Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud — Pierre-Bénite, Auvergne Rhone Alpe
- Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Saint-Eloi — Montpellier, Occitanie
- Centre Hospitalier Universitaire de Nantes (CHU de Nantes)-Hotel-Dieu — Nantes,
- Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Louis - Centre Integre en Cancerologie — Paris, Île-de-France Region
- Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona — Pamplona, Navarre
- Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS) — Seville,
📞 Contact the Study Coordinator
Phone: (917) 580-1088
Email: clinicaltrials@cellectis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in B-cell Non-Hodgkin Lymphoma (B-NHL)
- A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies — Chicago, Illinois
- A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma — Ciudad Autonoma de Buenos Aires, Buenos Aires
- Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies — Miami, Florida
Explore by condition: All B-cell Non-Hodgkin Lymphoma (B-NHL) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.